AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02595944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02595944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02595944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02595944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02595944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02595944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02595944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Undergo observation
Study NCT02595944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study NCT02595944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study NCT06167122 — intervention group
Intervention type: PROCEDURE
Intervention: Craniofacial reconstruction
Description: Zone 1 lesions: radical excision and immediate reconstruction with bone grafts for fibrous dysplasia lesions.~Zone 2 lesions: trimming \& recontouring. Zone 3 lesions: observation or conservative recontouring; optic nerve decompression performed when continuous deterioration of vision, and external auditory canal surgery performed when cholesteatoma/near total ear canal stenosis.~Zone 4: observation or conservative recontouring; orthognathic surgery performed when malocclusion or midface retrusion noted.
Study NCT01777711 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Contrasting- Individual
Description: Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
Study NCT01777711 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Contrasting- Couple
Description: Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
Study NCT03437265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLENVU powder for oral solution
Description: PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)
Study NCT03289845 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BHX implant (Bone anchored hearing system)
Description: Bone anchored hearing system for hearing rehabilitation
Study NCT02656186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-intervention
Description: First 2-weeks : keeping routine dietary habit
Study NCT02656186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid nutritional supplement
Description: Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
Study NCT00570609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR Anytime education
Description: After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
Study NCT03787641 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Protamine Sulfate
Description: Protamine Sulfate will be administered via an infusion pump to administer a 50 mg test doze, then 100 mg after 5 min waiting period. Following blood samples, additional alliquots of 50 mg will be measured to a maximum of 300 mg.
Study NCT04158245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine PET Scan
Description: The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.
Study NCT00695162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: quiet
Description: no noise
Study NCT00695162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-speech noise
Description: noise without speech
Study NCT00695162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: speech noise
Description: noise with speech present
Study NCT00727480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.
Study NCT02892747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Program
Study NCT04102085 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02138539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal depigmenting agent (Epionce)
Description: A two product herbal pigmentation reducing regimen is applied twice a day to either the left or right side of the face for a duration of 4 months.
Study NCT02138539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone
Description: Hydroquinone 4% is applied twice a day to either the left or right side of the face for a duration of 4 months.
Study NCT03953287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: A randomized, cross over design
Study NCT00742547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
Study NCT01727947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSOME
Description: A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied > 13% of nuclear area) in each sample will be assessed.
Study NCT04070547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device 4hours a day at 25Hz, 250 μs pulse width placed on tragus.
Study NCT04070547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Sham stimulation will be performed using electrodes 4 hours a day placed on earlobe.
Study NCT01666262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine A/17/CA/2009/38 (H1N1)
Description: Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
Study NCT01666262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo:Stabilizer
Description: 5% sucrose
Study NCT01045681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine, Velcade and Dexamethasone
Description: Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
Study NCT04028180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: p-Menthane,3-8-diol (PMD) Topical Repellent
Description: p-Menthane,3-8-diol (PMD) is a recommended active ingredient, which has been evaluated for safe use by the U.S. Environmental Protection Agency (USEPA)1. According to the USEPA laboratory exposure of animals to the active ingredient, PMD, this resulted in no adverse effects except eye irritation. The eye irritation potential of the finished product formulation has not been studied; therefore as a precaution, the products will be handled in the same way as the active ingredient. The researcher and participant must wear eye protection during application of the product and the potential for eye irritation is described in the Participant Information Sheet. . Participants will be excluded if they have a known allergy to any of the product ingredients, or any skin condition, which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human.
Study NCT04028180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picaridin Topical Repellent
Description: Icaridin (trade names include Picaridin) is a known mosquito and midge repellent active ingredient. The active ingredient, Picaridin, has been classified as potentially mildly irritating/uncomfortable to the eyes - participants and researcher will wear safety glasses during handling of the products and the participants will be warned about the potential for irritation during the Informed Consent Procedure. Participants will also be excluded if they have a known allergy to any of the product ingredients, or any skin condition which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human.
Study NCT02083328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
Study NCT02083328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Mannitol)
Description: Mannitol filled in gelatine capsules
Study NCT00966589 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: laparoscopic hernioplasty (TEP)
Description: Insertion of polypropylene mesh behind pubic bone
Study NCT00966589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic hernioplasty (TEP)
Description: Insertion of polypropylene mesh behind pubic bone
Study NCT03019549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study NCT03720691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real rTMS Supplementary motor area
Description: There will be a series of four rTMS blocks separated by 10 minutes. Each block will consist of 15 to 25 pulse trains of 1-second duration at 25 Hz, with an intertrain interval of 10 seconds.
Study NCT03720691 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS Supplementary motor area
Description: There will be no real brain stimulation in Sham rTMS, and participant will be blinded.
Study NCT04456881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with patellar dislocation undergo patellar femoral medial reconstruction
Description: Arthroscopic double-beam anatomical reconstruction of medial patellofemoral ligament
Study NCT04979663 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
Description: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
Study NCT03019549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally
Study NCT05366608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum level of 14.0- 3.0- 3.0- η protein and IL_.6
Description: Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.
Study NCT01959360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct lateral
Description: Total hip replacement; direct lateral approach
Study NCT01959360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal invasive
Description: Total hip replacement; minimal invasive approach
Study NCT03122535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FS-LASIK 70 degree side-cut angle
Description: FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
Study NCT03122535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FS-LASIK 110 degree side-cut angle
Description: FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
Study NCT01948167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy- Adolescent Skills Training
Description: A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.
Study NCT01948167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping with Stress
Description: A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
Study NCT00526188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetic Acid Disodium (Primovist, BAY86-4873)
Description: Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
Study NCT03716466 — intervention group
Intervention type: OTHER
Intervention: Endotracheal intubation
Description: Subjects will receive prophylactic endotracheal intubation for upper gastrointestinal endoscopy procedure
Study NCT03716466 — intervention group
Intervention type: OTHER
Intervention: No airway intervention
Description: Subjects without prophylactic endotracheal intubation during upper gastrointestinal endoscopy procedure
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine
Description: Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
Study NCT01959360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified minimal invasive
Description: Total hip replacement; modified minimal invasive approach
Study NCT02189265 — intervention group
Intervention type: OTHER
Intervention: Smoke-free legislation
Description: The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
Study NCT02693964 — intervention group
Intervention type: OTHER
Intervention: Bone density and carotid ultrasound
Description: All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
Study NCT02082561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Treatment (F-SET)
Description: F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
Study NCT02463942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
Study NCT02463942 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Symptomatic therapy
Description: Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
Study NCT02463942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study NCT02528695 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT
Study NCT02528695 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT
Study NCT02528695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: euglycemic clamp
Description: euglycemic clamp
Study NCT02528695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypoglycemic clamp
Description: hypoglycemic clamp
Study NCT02528695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hypoglycemic clamp
Description: hypoglycemic clamp
Study NCT03792009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paracervical block
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study NCT03792009 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Paracervical block
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study NCT03792009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% bupivacaine
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study NCT03792009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study NCT01479972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: Tuberculosis vaccine
Study NCT01479972 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: commercially available live vaccine BCG
Study NCT03118843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Study NCT00124618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00124618 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00052377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT00052377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given SC